Inactive Instrument

Highlights Oxis International Euronext Paris

Equities

US6918294025

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-

05-21	Top Midday Decliners	MT
05-21	GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	05-21	MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	05-21	MT
Top Premarket Gainers	05-20	MT
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	12-04	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	11-06	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
North American Morning Briefing : Hopes Build for -3-	15/05/23	DJ
GT Biopharma, Inc. Announces Board Changes	04/05/23	CI
North American Morning Briefing : Traders Await -3-	31/03/23	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	31/10/22	CI
GT Biopharma Taps Cytovance Biologics as Manufacturing Partner for Leukemia Drug	31/08/22	MT
Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650	30/08/22	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	28/03/22	CI
GT Biopharma Announces TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data	21/03/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oxis International Euronext Paris

Equities

US6918294025

Highlights

Filters